<SEC-DOCUMENT>0001493152-25-017378.txt : 20251008
<SEC-HEADER>0001493152-25-017378.hdr.sgml : 20251008
<ACCEPTANCE-DATETIME>20251008090505
ACCESSION NUMBER:		0001493152-25-017378
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251008
FILED AS OF DATE:		20251008
DATE AS OF CHANGE:		20251008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nasus Pharma Ltd
		CENTRAL INDEX KEY:			0002029039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				516022712
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42796
		FILM NUMBER:		251381317

	BUSINESS ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
		BUSINESS PHONE:		972 54-255-3956

	MAIL ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the month of October 2025 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-42796</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yigal
Alon 65</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel
Aviv, Israel 6744317</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, Nasus Pharma Ltd. (the &ldquo;Company&rdquo;) extended its collaboration with AptarGroup, Inc. and its affiliates through
the execution of a series of agreements designed to advance the development and commercialization of the Company&rsquo;s intranasal Epinephrine
program. The Company and AptarGroup Inc. have a history of collaboration dating back to 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, the Company and AptarGroup, Inc. (&ldquo;Aptar&rdquo;) entered into a Termination and Settlement Agreement (the &ldquo;Termination
Agreement&rdquo;) to: (i) terminate that certain Master Services Agreement by and between the Company and Aptar entered into on September
6, 2019 (the &ldquo;2019 Aptar MSA&rdquo;); (ii) terminate the schedules of work relating to Naloxone and Epinephrine entered into on
September 6, 2019 and April 20, 2020, respectively; and (iii) resolve and settle outstanding disputes between the parties related
to the 2019 Aptar MSA. In addition, on October 6, 2025, the Company and Aptar France S.A.S. (&ldquo;Aptar France&rdquo;) entered into
a new master services agreement (the &ldquo;2025 Aptar MSA&rdquo;), a schedule of work relating to the Company&rsquo;s Epinephrine program
(the &ldquo;2025 SOW&rdquo;), and a short-form supply agreement (the &ldquo;Supply Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2025
MSA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2025 Aptar MSA replaces the 2019 Aptar MSA and updates terms and conditions under which Aptar will provide development, analytical, regulatory,
and consulting services to the Company, including services enumerated in schedules of work signed by the parties for fees set forth in
such schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2025 Aptar MSA includes customary provisions regarding confidentiality, intellectual property, indemnification, and termination rights.
The 2025 Aptar MSA remains in effect until the later date of five years from the signing date, or until the services are completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>2025
SOW</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the 2025 Aptar MSA, the parties entered into a schedule of work related to Epinephrine on October 6, 2025. Under the 2025 SOW, Aptar
France will provide support for the development, testing, and regulatory submission of the Company&rsquo;s intranasal Epinephrine powder
delivered through Aptar&rsquo;s Unit Dose Powder nasal delivery system (&ldquo;UDSp&rdquo;) device. In consideration for such services,
the Company has agreed to pay Aptar France staged fees over the next three years, milestone payments upon (i) new drug application (&ldquo;NDA&rdquo;)
submission and (ii) NDA approval, and royalties stemming from commercial sales of the intranasal Epinephrine product for a period of
seven years commencing on the date of the first commercial sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supply
Agreement </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2025, the Company and Aptar France entered into a Supply Agreement relating to the Company&rsquo;s Epinephrine program. The
Supply Agreement provides that, subject to U.S. Food and Drug Administration approval of the underlying program, Aptar France will exclusively
supply the Company with UDSp devices, with the Company committing to purchase 100% of its requirements from Aptar France for use in its
products for Epinephrine. The Supply Agreement has an initial term of five years, is renewable for two years, and sets forth pricing
on a per-component basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Press
Release </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2025, the Company issued a press release titled &ldquo;Nasus Pharma Announces Expanded Agreement to Support Development and
Commercialization of NS002 Intranasal Epinephrine Program,&rdquo; a copy of which is furnished as Exhibit 99.1 to this Report of Foreign
Private Issuer on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
INDEX</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release issued on October 8, 2025 by Nasus Pharma Ltd. titled &ldquo;Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program&rdquo;.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS PHARMA LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    October 8, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ Dan Teleman</I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
Teleman </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasus
Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Strategic
collaboration with leading global manufacturer of drug delivery systems strengthens NS002&rsquo;s clinical and commercial roadmap with
end-to-end development support and manufacturing infrastructure</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, October 8, 2025 &mdash; Nasus Pharma Ltd. (NYSE: NSRX) (&ldquo;Nasus Pharma&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage
pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced
the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, &ldquo;Aptar&rdquo;), a leading
global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus
Pharma&rsquo;s intranasal powder epinephrine product candidate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
collaboration represents a significant milestone for Nasus Pharma and for our NS002 program,&rdquo; said Dan Teleman, Chief Executive
Officer of Nasus Pharma. &ldquo;Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology,
providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways,
manufacturing capabilities and supply chain, accelerating NS002&rsquo;s path to market while reducing development risks.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the
U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) and the European Medicines Agency (the &ldquo;EMA&rdquo;). This strategic relationship
provides Nasus with access to Aptar&rsquo;s technical expertise and manufacturing capabilities to advance NS002 through current clinical
development to commercialization in alignment with Nasus Pharma&rsquo;s timeline and objectives.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nasus Pharma</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions
in the community. NS002, Nasus&rsquo;s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative
to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which
rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (&ldquo;PBI&rdquo;)
technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity&rsquo;s rich vascular network for quick absorption.
The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to
liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on <U>Twitter (X)</U>
or <U>Linkedin</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of
1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release
are forward-looking statements, including, among other things: statements regarding the development and commercialization of NS002; the
potential benefits of the collaboration with Aptar; the potential market opportunity for NS002; and that the collaboration with Aptar
is accelerating NS002&rsquo;s path to market while reducing development risks. Forward-looking statements contained in this press release
may be identified by the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo;
&ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on the Company&rsquo;s current expectations and are subject to uncertainties,
risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s prospectus related to filed with the U.S. Securities and Exchange Commission dated August 12, 2025.
Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
Pharma Ltd.<BR>
info@nasuspharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arx
Investor Relations<BR>
North American Equities Desk<BR>
nasus@arxhq.com</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ &@# 2(  A$! Q$!_\0
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MMN?#;X+? ?2/AK\4=1O? GBC0);B)H=6TZ=5E1I6==I5"00&P0P'3OFO*?\
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(23^-%,1__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
